At day 18 post intracranial tumor implantation, we thus did not observe any changes in T cell populations in the periphery for any treatment group, however, the primary tumor site did exhibit significant changes in both CD4+ and CD8+ T cell percentages in the triple treatment group as well as the anti-4-1BB and anti-CTLA-4 double treatment group. The gene discussed is CTLA4; the disease is neoplasm.